Abstract

Objective: This study aims to Formulate Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate with the increase in bioavailability and patient compliance. Methods: Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate were developed by full factorial design at 32levelsand prepared by direct compression method using super integrants like sodium starch glycolate, Ludiflash. The tablets were compressed into compacts on a 10 station tablet machine. The bulk drug was characterised by determining, MP, Solubility, pH and FTIR spectra. Results: The weight variation, hardness and diameter, thickness, friability, drug content, wetting time, in vitro disintegration time and in vitro dissolution studies, and stability study, tablet thickness, weight variation and drug content post compression parameters remained consistent and reproducible. All the formulations showed, almost 100 percent of drug release within 75 min. Formulations F1, F2 and F3 were prepared with 5 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F1<F2<F3. Formulations F4, F5 and F6 were prepared with 10 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F4<F5<F6. Formulations F7, F8 and F9 were prepared with 15 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F7<F8<F9. Conclusion: It is concluded that the amount of superdisintegrants decreases disintegration time of tablets, decreases wetting time, increases the cumulative % drug release causes better absorption.

Highlights

  • Mouth Dissolving Tablets (MDTs) dissolve or disintegrate in saliva and are swallowed without the need of water

  • The apparent bulk densities for all formulated batches were found to be in between 0.543±0.023 gm/ml and 0.586±0.028 gm/ml Bulk densities were found in acceptable limits, which indicating that the packing properties required during compression are adequate in all formulations

  • Tofacitinib Citrate was characterized by studying its absorbance, melting point, Partition coefficient and solubility in water, and various solvents and FTIR spectroscopy

Read more

Summary

Introduction

Mouth Dissolving Tablets (MDTs) dissolve or disintegrate in saliva and are swallowed without the need of water. MDTs offer an advantage over the conventional tablets because of their convenience of easy manufacturing, self-administration, Compactness It improves the onset of action, increases bioavailability, and stability which helps to improve the choice of the dosage form in the current market [1, 2]. The demand for the development of Mouth Dissolving Tablets (MDTs) has hugely increased as it has better compliance in patients [4]. Tofacitinib citrate is a Janus kinase JAK1/JAK3 inhibitor class [8]. It is currently developed by Pfizer for treating severe active rheumatoid arthritis in adult patients [9]. The aim of this study to prepare mouth dissolving tablets of Tofacitinib Citrate used to treat certain types of arthritis [13]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call